High intratumoral expression of eIF4A1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer. (6th March 2020)

• Record Type: Journal Article
• Authors: Gao, Chanchan; Guo, Xinyin; Xue, Anwei; Ruan, Yuanyuan; Wang, Hongshan; Gao, Xiaodong
• Is Part Of: Acta biochimica et biophysica Sinica. Volume 52:Number 3(2020)
• Page Start: 310
• Page End: 319
• Publication Date: 2020-03-06
• Subjects: eIF4A1 -- gastric cancer -- epithelial-to-mesenchymal transition -- prognostic factor; Biochemistry -- Periodicals; Biophysics -- Periodicals; 572.05
• DOI: 10.1093/abbs/gmz168
• Languages: English
• ISSNs: 1672-9145

Abstract

Abstract: Gastric cancer is an important health problem, being the fifth most common cancer and the third leading cause of cancer-related death worldwide. Aberrant protein translation contributes to the oncogenesis and development of cancers, and upregulation of translation initiation factor eIF4A1 has been observed in several kinds of malignancies. However, the role of eIF4A1 in gastric cancer progression remains unclear. In this study, we found that the expression of eIF4A1, a component of translation initiation complex, was increased in gastric cancer. High expression of eIF4A1 was positively associated with poor tumor differentiation, late T stage, lymph node metastasis, advanced TNM stage, and poor prognosis in patients with gastric cancer. Overexpression of eIF4A1 promoted the migration and invasion of gastric cancer cells in vitro and enhanced tumor metastasis in nude mice model. Mechanism studies revealed that eIF4A1 induced epithelial-to-mesenchymal transition (EMT) of gastric cancer cells through driving the translation of SNAI1 mRNA. Together, these findings indicate that eIF4A1 promotes EMT and metastasis of gastric cancer and suggest that eIF4A1 is a potential target for the adjuvant therapy for gastric cancer patients.